Vaxxa has, after the publication of the year-end report for 2025, reassessed the value of certain receivables. "Following the emergence of new information, this reassessment has led to a write-down of certain receivables of approximately SEK 5.2 million," the company writes in a press release.This adjustment means that the company's results for the full year and the fourth quarter of 2025, as previously communicated in the year-end report on February 24, decrease by approximately SEK 5.2 million. Following the adjustment, the company's result amounts to approximately SEK -9.35 million for the full year 2025 and approximately SEK -6.58 million for the fourth quarter.It is important to note that the write-down does not affect cash flow and does not affect the company's liquidity, the company writes.